The Emerging Role of Liquid Biopsy in Gastric Cancer.
Csongor György LengyelSadaqat HussainDario TrapaniKhalid El BairiSara Cecilia AltunaAndreas SeeberAndrew OdhiamboBaker Shalal HabeebFahmi SeidPublished in: Journal of clinical medicine (2021)
(1) Background: Liquid biopsy (LB) is a novel diagnostic method with the potential of revolutionizing the prevention, diagnosis, and treatment of several solid tumors. The present paper aims to summarize the current knowledge and explore future possibilities of LB in the management of metastatic gastric cancer. (2) Methods: This narrative review examined the most recent literature on the use of LB-based techniques in metastatic gastric cancer and the current LB-related clinical trial landscape. (3) Results: In gastric cancer, the detection of circulating cancer cells (CTCs) has been recognized to have a prognostic role in all the disease stages. In the setting of localized disease, cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) qualitative and quantitative detection have the potential to inform on the risk of cancer recurrence and metastatic dissemination. In addition, gastric cancer-released exosomes may play an essential part in metastasis formation. In the metastatic setting, the levels of cfDNA show a positive correlation with tumor burden. There is evidence that circulating tumor microemboli (CTM) in the blood of metastatic patients is an independent prognostic factor for shorter overall survival. Gastric cancer-derived exosomal microRNAs or clonal mutations and copy number variations detectable in ctDNA may contribute resistance to chemotherapy or targeted therapies, respectively. There is conflicting and limited data on CTC-based PD-L1 verification and cfDNA-based Epstein-Barr virus detection to predict or monitor immunotherapy responses. (4) Conclusions: Although preliminary studies analyzing LBs in patients with advanced gastric cancer appear promising, more research is required to obtain better insights into the molecular mechanisms underlying resistance to systemic therapies. Moreover, validation and standardization of LB methods are crucial before introducing them in clinical practice. The feasibility of repeatable, minimally invasive sampling opens up the possibility of selecting or dynamically changing therapies based on prognostic risk or predictive biomarkers, such as resistance markers. Research is warranted to exploit a possible transforming area of cancer care.
Keyphrases
- circulating tumor
- circulating tumor cells
- squamous cell carcinoma
- cell free
- prognostic factors
- small cell lung cancer
- epstein barr virus
- copy number
- minimally invasive
- clinical trial
- systematic review
- clinical practice
- healthcare
- real time pcr
- end stage renal disease
- loop mediated isothermal amplification
- mitochondrial dna
- ultrasound guided
- high resolution
- ejection fraction
- genome wide
- chronic kidney disease
- diffuse large b cell lymphoma
- locally advanced
- young adults
- neoadjuvant chemotherapy
- lymph node
- fine needle aspiration
- lymph node metastasis
- robot assisted
- drug induced
- big data
- quantum dots